glp-1 drugs cancer Could Reduce Obesity-Related Cancers in the Future? Glucagon-like peptide-1 medicines and cancer

doi: 10.1016/S2213-8587(22)00349-7

[PMID: 37940101]

When a target drug or metabolite is present in urine above a predetermined cutoff concentration, it binds to specific antibodies in the test reagent, producing a measurable signal

Partial agonism at GPCRs is not inherently disadvantageous and can, in some contexts, confer therapeutic benefits

Managing appetite, and maintaining healthy blood sugar levels, can be challenging

Specifically, STAT1 is thought to play a role in transcriptional regulation as the promoter region of DPP-4 contains an interferon-gamma-activated sequence (GAS), which is an activated STAT1 binding site